GSK Statistics
Total Valuation
GSK has a market cap or net worth of $78.50 billion. The enterprise value is $96.55 billion.
Important Dates
The last earnings date was Wednesday, July 30, 2025, before market open.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | May 16, 2025 |
Share Statistics
GSK has 4.05 billion shares outstanding. The number of shares has increased by 0.49% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.05B |
| Shares Change (YoY) | +0.49% |
| Shares Change (QoQ) | -0.65% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.88B |
Valuation Ratios
The trailing PE ratio is 34.57 and the forward PE ratio is 8.97.
| PE Ratio | 34.57 |
| Forward PE | 8.97 |
| PS Ratio | 1.81 |
| Forward PS | 4.65 |
| PB Ratio | 3.99 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 9.02 |
| P/OCF Ratio | 7.42 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 7.58, with an EV/FCF ratio of 11.10.
| EV / Earnings | 20.59 |
| EV / Sales | 2.23 |
| EV / EBITDA | 7.58 |
| EV / EBIT | 11.07 |
| EV / FCF | 11.10 |
Financial Position
The company has a current ratio of 0.87, with a Debt / Equity ratio of 1.21.
| Current Ratio | 0.87 |
| Quick Ratio | 0.56 |
| Debt / Equity | 1.21 |
| Debt / EBITDA | 1.83 |
| Debt / FCF | 2.73 |
| Interest Coverage | 10.25 |
Financial Efficiency
Return on equity (ROE) is 28.33% and return on invested capital (ROIC) is 12.75%.
| Return on Equity (ROE) | 28.33% |
| Return on Assets (ROA) | 6.78% |
| Return on Invested Capital (ROIC) | 12.75% |
| Return on Capital Employed (ROCE) | 16.38% |
| Revenue Per Employee | $631,454 |
| Profits Per Employee | $68,334 |
| Employee Count | 68,629 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.50 |
Taxes
In the past 12 months, GSK has paid $874.09 million in taxes.
| Income Tax | 874.09M |
| Effective Tax Rate | 13.80% |
Stock Price Statistics
The stock price has decreased by -2.95% in the last 52 weeks. The beta is 0.27, so GSK's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -2.95% |
| 50-Day Moving Average | 38.67 |
| 200-Day Moving Average | 36.92 |
| Relative Strength Index (RSI) | 57.99 |
| Average Volume (20 Days) | 5,341,287 |
Short Selling Information
The latest short interest is 12.53 million, so 0.62% of the outstanding shares have been sold short.
| Short Interest | 12.53M |
| Short Previous Month | 18.50M |
| Short % of Shares Out | 0.62% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.04 |
Income Statement
In the last 12 months, GSK had revenue of $43.34 billion and earned $4.69 billion in profits. Earnings per share was $1.13.
| Revenue | 43.34B |
| Gross Profit | 31.07B |
| Operating Income | 8.72B |
| Pretax Income | n/a |
| Net Income | 4.69B |
| EBITDA | 12.73B |
| EBIT | 8.72B |
| Earnings Per Share (EPS) | $1.13 |
Full Income StatementBalance Sheet
The company has $4.96 billion in cash and $23.78 billion in debt, giving a net cash position of -$18.82 billion or -$4.65 per share.
| Cash & Cash Equivalents | 4.96B |
| Total Debt | 23.78B |
| Net Cash | -18.82B |
| Net Cash Per Share | -$4.65 |
| Equity (Book Value) | 19.67B |
| Book Value Per Share | 5.01 |
| Working Capital | -3.71B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $10.58 billion and capital expenditures -$1.80 billion, giving a free cash flow of $8.70 billion.
| Operating Cash Flow | 10.58B |
| Capital Expenditures | -1.80B |
| Free Cash Flow | 8.70B |
| FCF Per Share | $2.15 |
Full Cash Flow StatementMargins
Gross margin is 71.69%, with operating and profit margins of 20.13% and 10.82%.
| Gross Margin | 71.69% |
| Operating Margin | 20.13% |
| Pretax Margin | 14.61% |
| Profit Margin | 10.82% |
| EBITDA Margin | 29.37% |
| EBIT Margin | 20.13% |
| FCF Margin | 20.08% |
Dividends & Yields
This stock pays an annual dividend of $1.58, which amounts to a dividend yield of 4.04%.
| Dividend Per Share | $1.58 |
| Dividend Yield | 4.04% |
| Dividend Growth (YoY) | 8.43% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 139.76% |
| Buyback Yield | -0.49% |
| Shareholder Yield | 3.56% |
| Earnings Yield | 5.97% |
| FCF Yield | 11.08% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 4.27% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 19, 2022. It was a reverse split with a ratio of 1:1.25.
| Last Split Date | Jul 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:1.25 |
Scores
GSK has an Altman Z-Score of 1.83 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.83 |
| Piotroski F-Score | 6 |